温肾健脾利水方联合缬沙坦胶囊治疗脾肾气虚型 慢性肾小球肾炎临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R692.31

基金项目:


Clinical Study on Wenshen Jianpi Lishui Prescription Combined with Valsartan Capsules in Treating Chronic Glomerulonephritis of Spleen- Kidney Qi Deficiency Type
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察温肾健脾利水方联合缬沙坦胶囊治疗脾肾气虚型慢性肾小球肾炎(CG) 临床疗效。方法:选取443 例CG 患者作为研究对象,按随机数字表法分为观察组222 例和对照组221 例。对照组予以缬沙坦胶囊治疗,观察组予以缬沙坦胶囊联合温肾健脾利水方治疗,2 组均持续治疗2 个月。观察2 组临床疗效及不良反应发生率,比较2 组治疗前后中医证候积分、肾功能指标[尿素氮(BUN)、血肌酐(SCr)、尿蛋白定量(Upr)] 及炎症因子[白细胞介素-6(IL-6)、C-反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)] 水平的变化。结果:观察组临床疗效总有效率为95.05%,对照组为90.05%,2 组比较,差异有统计学意义(P<0.05)。治疗后,2 组头晕目眩、尿液浑浊及尿血的中医证候积分均较治疗前下降(P<0.05),观察组上述3 项中医证候积分均低于对照组(P<0.05)。治疗后,2 组BUN、SCr、Upr 水平均较治疗前下降(P<0.05),观察组上述3 项水平均低于对照组(P<0.05)。治疗后,2 组CRP、IL-6、TNF-α 水平均较治疗前下降(P<0.05),观察组上述3 项水平均低于对照组(P<0.05)。治疗后,观察组不良反应发生率为4.95%,对照组为7.24%,2 组比较,差异无统计学意义(P>0.05)。结论:温肾健脾利水方联合缬沙坦胶囊治疗CG 可提高临床疗效,缓解临床症状,降低炎症反应,提高肾功能。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Wenshen Jianpi Lishui Prescription combined with Valsartan Capsules in treating chronic glomerulonephritis(CG) of spleen- kidney qi deficiency type. Methods:A total of 443 cases of CG patients were selected as the study objectives and divided into the observation group and the control group according to the random number table method, with 222 and 221 cases in each group respectively. The control group was treated with Valsartan Capsules, and the observation group was treated with Wenshen Jianpi Lishui Prescription combined with Valsartan Capsules. Both groups were treated for two months. Clinical effects and the incidences of adverse reactions in the two groups were observed. Changes in Chinese medicine syndrome scores, the kidney function indexes [blood urea nitrogen(BUN), serum creatinine(SCr), urine protein ratio(Upr)], and inflammatory factors [interleukin- 6(IL- 6) , C- reactive protein(CRP) , tumor necrosis factor- α (TNF- α )] before and after treatment in the two groups were compared. Results:The total clinical effective rate was 95.05% in the observation group and 90.05% in the control group, the difference being significant(P<0.05). After treatment, traditional Chinese medicine(TCM) syndrome scores of vertigo and dizzy vision, turbid urine, and bloody urine in the two groups were decreased when compared with those before treatment(P<0.05), and the above three TCM syndrome scores in the observation group were lower than those in the control group(P<0.05). After treatment, the levels of BUN, SCr, and URP in the two groups were decreased when compared with those before treatment(P<0.05),and the above three levels in the observation group were lower than those in the control group(P<0.05). After treatment,the levels of CRP,IL-6,and TNF-α in the two groups were decreased when compared with those before treatment (P<0.05),and the above three levels in the observation group were lower than those in the control group (P<0.05). After treatment, the incidence of adverse reactions was 4.95% in the observation group and 7.24% in the control group, there being no significance in the difference(P>0.05). Conclusion: In the treatment of CG, Wenshen Jianpi Lishui Prescription combined with Valsartan Capsules can enhance clinical effect, relieve clinical symptoms,reduce inflammatory responses,and improve the kidney function.

    参考文献
    相似文献
    引证文献
引用本文

杨琳,高淑婷,许欢.温肾健脾利水方联合缬沙坦胶囊治疗脾肾气虚型 慢性肾小球肾炎临床研究[J].新中医,2022,54(23):93-97

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-12-11
  • 出版日期:
文章二维码